Merrimack Pharmaceuticals
Market Cap
US$46.2m
Last Updated
2020/06/05 03:53 UTC
Data Sources
Company Financials
Executive Summary
Merrimack Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers.
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet and overvalued.
Share Price & News
How has Merrimack Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MACK's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
1.2%
MACK
-1.5%
US Biotechs
3.8%
US Market
1 Year Return
-40.9%
MACK
22.1%
US Biotechs
9.7%
US Market
Return vs Industry: MACK underperformed the US Biotechs industry which returned 23.9% over the past year.
Return vs Market: MACK underperformed the US Market which returned 8.9% over the past year.
Shareholder returns
| MACK | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.2% | -1.5% | 3.8% |
| 30 Day | -11.6% | 3.5% | 11.4% |
| 90 Day | 6.2% | 9.0% | 6.8% |
| 1 Year | -15.4%-40.9% | 23.3%22.1% | 12.1%9.7% |
| 3 Year | -65.9%-76.2% | 26.1%22.1% | 36.2%27.2% |
| 5 Year | -93.4%-96.9% | -5.5%-11.0% | 63.7%45.4% |
Price Volatility Vs. Market
How volatile is Merrimack Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
What Type Of Shareholder Owns Merrimack Pharmaceuticals, Inc.'s (NASDAQ:MACK)?2 months ago | Simply Wall St
Does The Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Share Price Tend To Follow The Market?3 months ago | Simply Wall St
Here's Why Merrimack Pharmaceuticals (NASDAQ:MACK) Must Use Its Cash WiselyValuation
Is Merrimack Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
2.54x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MACK's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MACK's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MACK is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: MACK is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MACK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MACK is good value based on its PB Ratio (2.5x) compared to the US Biotechs industry average (3.7x).
Next Steps
Future Growth
How is Merrimack Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
30.0%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Merrimack Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine Merrimack Pharmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has Merrimack Pharmaceuticals performed over the past 5 years?
27.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MACK is currently unprofitable.
Growing Profit Margin: MACK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MACK is unprofitable, but has reduced losses over the past 5 years at a rate of 27.7% per year.
Accelerating Growth: Unable to compare MACK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MACK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: MACK has a negative Return on Equity (-58.52%), as it is currently unprofitable.
Next Steps
Financial Health
How is Merrimack Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: MACK's short term assets ($20.0M) exceed its short term liabilities ($3.3M).
Long Term Liabilities: MACK has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: MACK is debt free.
Reducing Debt: MACK currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MACK has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MACK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Merrimack Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MACK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MACK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MACK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MACK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MACK's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.2yrs
Average management tenure
CEO
Gary Crocker (67yo)
1
Tenure
US$95,258
Compensation
Mr. Gary L. Crocker, MBA, has been President (Principal Executive Officer) and Treasurer (Principal Financial and Accounting Officer) of Merrimack Pharmaceuticals, Inc. since June 28, 2019. He is Chief Exe ...
CEO Compensation Analysis
Compensation vs Market: Gary's total compensation ($USD95.26K) is below average for companies of similar size in the US market ($USD577.87K).
Compensation vs Earnings: Gary's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1yr | US$95.26k | 3% $1.4m | |
| Co-Founder & Independent Director | 5.42yrs | US$84.48k | 0.17% $78.2k | |
| Co-Founder and Scientific Advisor | no data | US$24.75k | no data | |
| Senior Director of Communications | no data | no data | no data | |
| Head of Human Resources | 3.08yrs | no data | no data | |
| Senior Vice President of Manufacturing | 14.17yrs | US$690.77k | no data | |
| Head of Research | 3.25yrs | US$817.30k | no data | |
| Secretary | no data | no data | no data |
3.2yrs
Average Tenure
59yo
Average Age
Experienced Management: MACK's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1yr | US$95.26k | 3% $1.4m | |
| Co-Founder & Independent Director | 5.42yrs | US$84.48k | 0.17% $78.2k | |
| Member of Scientific Advisory Board | 2.33yrs | US$39.38k | no data | |
| Independent Director | 5.42yrs | US$82.04k | 0.0075% $3.4k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 2.42yrs | no data | no data | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 0.75yr | no data | no data | |
| Member of Scientific Advisory Board | 2.33yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.33yrs | no data | no data |
2.4yrs
Average Tenure
62yo
Average Age
Experienced Board: MACK's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Merrimack Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Merrimack Pharmaceuticals, Inc.
- Ticker: MACK
- Exchange: NasdaqGM
- Founded: 1993
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$46.162m
- Shares outstanding: 13.38m
- Website: https://www.merrimack.com
Number of Employees
Location
- Merrimack Pharmaceuticals, Inc.
- One Broadway
- 14th Floor
- Cambridge
- Massachusetts
- 2142
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MACK | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Mar 2012 |
| MP6N | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Mar 2012 |
| MP6N | BST (Boerse-Stuttgart) | Yes | Common Stock | DE | EUR | Mar 2012 |
Biography
Merrimack Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5. The company has a collaboration and license agreement with Ipsen S.A. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is based in Cambridge, Massachusetts.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/05 03:53 |
| End of Day Share Price | 2020/06/04 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.